North Carolina Attorney General Jeff Jackson discusses the $7.4 billion opioid settlement reached with Purdue Pharma, the ...

Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential ...

Indian pharmaceutical companies are preparing to flood the market with generic versions of Novo Nordisk’s semaglutide—sold ...

Kiniksa Pharmaceuticals sees strong growth from Arcalyst, aided by Medicare redesign. Learn about 2025 sales outlook & ...

Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, ...

Advent International is set to invest $175 million in Felix Pharmaceuticals, acquiring a significant minority stake. Felix ...

Alfasigma, the prescription, OTC, and supplement-maker born in Bologna, Italy, announced in a press conference held in ...

Across the recent three months, 11 analysts have shared their insights on ACADIA Pharmaceuticals ACAD, expressing a variety ...

Appointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with ...

Felix Pharma, a global leader in off-patent animal medicines, secures $175 million investment from Advent for expansion.

2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role ...